Incyte
INCY · NASDAQ · USD · Healthcare
1What is happening
Incyte has fallen 5% since its 6-week high on 28/09/2026. How it continues – phase and signs – you see with a free account.
Free account · 3 stocks and coins a dayfrom the 6-week high-5.1%
Other view · 24 analystsHorizon: 12 months13 Buy · 14 Hold · 1 Sell2Our assessment
No dip44How it continues – phase and signs – you see with a free account.
3Your next step
Marking places no order – it only helps you keep track.
More details · reasons, figures, alerts
How deep is the dip?
- from the 6-week high-5.1%
Highest daily price: $126.14 on 28/09/2026 · reference of the assessment
- from the 3-month high-8.5%
Highest daily price in 3 months: $130.80 on 25/08/2026
- from the 52-week high-9.8%
Highest price in 52 weeks: $132.60 (Yahoo)
What analysts expect
24 analysts disagree. They look about 12 months ahead – DipCatcher only 14 trading days.
- Buy
- 1346 %
- Hold
- 1450 %
- Sell
- 14 %
Average price target$131.50
$100.00 to $157.00 · today $119.65
$100.00Ø $131.50$157.00
What is a price target?
The price an analyst expects in about 12 months. Estimates are often far apart and change frequently.
Third-party opinion, not an assessment by DipCatcher. Source: public analyst estimates, as of 08/11/2026. Not financial advice.
The company in figures
- Market value
- 24.4 bn $
- All shares together at the current price.
- P/E
- 61.1
- Price divided by earnings per share, last 12 months.
- 52-week range
- $89.25 – $132.60
- Lowest and highest price of the last year.
Catalysts
37 h ago- News, last 10 days
- no recent news
- Next earnings
- —
- Last report
- 29/10/2026 +6.9% vs estimate
Key figures
- Market value
- 24.4 bn $Large cap
- P/E
- 61.1
- Volume today
- 0.9 × Øabout usual
- Beta
- 0.78swings about like the market
- 52-week range
- $89.25 – $132.60price at 70 % of the range
About Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. Incyte Corporation has a clinical trial collaboration with Genmab A/S to evaluate petosemtamab. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
- Headquarters:
- Wilmington, United States
- 52-week range:
- $89.25 – $132.60
- Website:
- incyte.com
Trade levels
Why the engine says so
History for this stock or coin
Watch and alert
See which stocks they are
The engine is watching these dips right now. A free account shows the names and opens 3 full analyses a day.
- 3 full analyses a dayWith entry, target, stop and the reasons behind them.
- WatchlistFollow the stocks you care about.
Free, no payment details.
Signals are generated automatically from price, volume and technical indicators. They are not investment advice.← Back to search
Not investment advice. Investing carries risk up to total loss.